Atlanta, GA 的 三陰性乳癌 臨床試驗
20 項針對 三陰性乳癌 的研究正在 Atlanta（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- Emory University, Atlanta
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Emory Winship Cancer Institute, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
招募中2 期
- Emory University (Data Collection Only), Atlanta
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
招募中1 期
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
招募中2 期
- Emory University, Atlanta
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
招募中1/2 期
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Northside Hospital, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Winship Cancer Institute, Emory University, Atlanta
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- Winship Cancer Institute, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- Winship Cancer Institute / Emory University, Atlanta
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
招募中2 期
- Emory University Hospital, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
招募中觀察性研究歡迎健康志工
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- Winship Cancer Institute of Emory University, Atlanta
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
招募中2 期
- Emory University Hospital/Winship Cancer Institute, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
招募中1 期
- Emory University, Winship Cancer Institute, Atlanta
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
招募中1/2 期
- Winship Cancer Institute - Emory University, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
招募中1 期
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 還有 1 項
A Beta-only IL-2 ImmunoTherapY Study
招募中1/2 期
- Emory - Winship Cancer Institute, Atlanta
其他城市的 三陰性乳癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Los Angeles, CA27 項研究
- Boston, MA26 項研究
- San Antonio, TX23 項研究
- St. Louis, MO21 項研究
- Arlington, VA20 項研究
- Dallas, TX18 項研究
- Chicago, IL16 項研究
- Columbus, OH16 項研究
- Grand Rapids, MI15 項研究
Atlanta 的其他研究
- 癌症（所有類型）49 項研究
- 非小細胞肺癌47 項研究
- 多發性骨髓瘤42 項研究
- 乳癌41 項研究
- 前列腺癌33 項研究
- 急性髓系白血病31 項研究
- 卵巢癌29 項研究
- 大腸直腸癌29 項研究
- 肺癌29 項研究
- 轉移性癌症28 項研究
- 重度憂鬱症25 項研究
- 心臟衰竭25 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。